The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH 2017 | Developing an understanding of disease progression in MDS and AML
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) increasingly appear to be influenced by genetic features, with new research attempting to provide a clearer understanding of how genetic predisposition can lead to the development of these diseases and their altered signaling pathways. In this interview, Jane Churpek, MD, of the University Chicago, IL, discusses the research currently underway in this area, such as that looking at germline RUNX1 mutations, and highlights the importance of having an understanding of disease progression. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
